Back to results
US 2009/0275567 A1Published application
2-heterocycloamino-4-imidazolylpyrimidines as agents for the inhibition of cell proliferation
OwnerClifford Jones, Martin Pass +1inventors
InventorsClifford Jones, Martin Pass, David Rudge
Life of this patent
Estimating the term…
Abstract
Compounds of formula (I): which possess cell-cycle inhibitory activity are described.
Claims19
1:
- A compound of formula (I):
- wherein:
- Ring A is a 5-7 membered saturated heterocyclic ring which contains one nitrogen atom and optionally 1 or 2 additional heteroatoms selected from N, O or S;
- wherein 2 atoms of Ring A may optionally be connected by a bridge;
- R1 is a substituent on nitrogen and is selected from hydrogen, C1-6alkyl, C1-6alkanoyl, carbamoyl, N,N—(C1-6alkyl)carbamoyl, N,N—(C1-6alkyl)carbamoyl, N—(C1-6alkenyl)carbamoyl, N,N—(C1-6alkenyl)carbamoyl, sulphamoyl, N—(C1-6alkyl)sulphamoyl, N,N—(C1-6alkyl)2sulphamoyl, N—(C1-6alkenyl)sulphamoyl, N,N—(C1-6alkenyl)sulphamoyl, C1-6alkoxycarbonyl, C1-6alkylsulphonyl, C1-6alkenylsulphonyl, carbocyclyl-R6 or heterocyclyl-R7;
- wherein R1 may be optionally substituted on carbon by one or more R8;
- and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R9;
- R2 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl. C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N—(C1-6alkyl)amino, N,N—(C1-6alkyl)2amino, C1-6alkanoylamino, N—(C1-6alkyl)carbamoyl, N,N—(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, N—(C1-6alkyl)sulphamoyl, N,N—(C1-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino, carbocyclyl-R10— or heterocyclyl-R11—;
- wherein R2 may be optionally substituted on carbon by one or more R12;
- and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R13;
- q is 0-4;
- wherein the values of R2 may be the same or different;
- R3 is selected from halo, cyano or amino;
- n is 0 to 2, wherein the values of R3 may be the same or different;
- R4 is selected from ethyl, propyl, isopropyl, butyl, iso-butyl, sec-butyl, t-butyl, cyclopropyl, cyclopropylmethyl, 1-cyclopropylethyl, cyclobutylmethyl, cyclopentyl or cyclobutyl;
- wherein R4 may be optionally substituted on carbon by one or more R14;
- R5 is selected from methyl, ethyl, isopropyl, fluoromethyl, difluoromethyl, trifluoromethyl, methoxymethyl, cyclopropylmethyl or cyclopropyl;
- R6 and R7 are independently selected from —C(O)—, —C(O)N—(R15)—, —S(O)2— or —SO2N—(R16)—;
- wherein R15 and R16 are independently selected from hydrogen or C1-6alkyl;
- R8and R12 are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N—(C1-6alkyl)amino, N,N—(C1-6alkyl)2amino, C1-6alkanoylamino, N—(C1-6alkyl)carbamoyl, N,N—(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, N—(C1-6alkyl)sulphamoyl, N,N—(C1-6alkyl)2sulphamoyl, C1-6alkylsulphonylamino, carbocyclyl-R17— or heterocyclyl-R18—;
- wherein R8 and R12 independently of each other may be optionally substituted on carbon by one or more R19;
- and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R20;
- R9, R13 and R20 are independently selected from C1-6alkyl, C1-6alkanoyl, C1-6alkylsulphonyl, C1-6alkoxycarbonyl, carbamoyl, N—(C1-6alkyl)carbamoyl, N,N—(C1-6alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;
- wherein R9, R13 and R20 independently of each other, may be optionally substituted on carbon by one or more R21;
- R10, R11, R17 and R18 are independently selected from a direct bond, —O—, —N—(R22)—, —C(O)—, —N—(R23)C(O)—, —C(O)N—(R24)—, —S(O)s—, —SO2N—(R25)— or —N—(R26)SO2—;
- wherein R22, R23, R24, R25 and R26 are independently selected from hydrogen or C1-6alkyl and s is 0-2;
- R14 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkoxy, C1-6alkanoyl, C1-6alkanoyloxy, N—(C1-6alkyl)amino, N,N—(C1-6alkyl)2amino, C1-6alkanoylamino, N—(C1-6alkyl)carbamoyl, N,N—(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, N—(C1-6alkyl)sulphamoyl, N,N—(C1-6alkyl)2sulphamoyl and C1-6alkylsulphonylamino;
- and
- R19 and R21 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, N,N-dimethylsulphamoyl, N,N-diethylsulphamoyl or N-methyl-N-ethylsulphamoyl;
- or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof.
27 more elements
2:
- A compound of formula (I), or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof, as claimed in claim 1 wherein Ring A is azepan-3-yl, 3-azabicyclo[3.1.0]hexan-3-yl, piperidin-3-yl, piperidin-4-yl, pyrrolidin-3-yl or 8-azabicyclo[3.2.1]octan-3-yl.
3:
- A compound of formula (I), or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof, as claimed in claim 1 wherein R1 is a substituent on nitrogen and is selected from hydrogen, C1-6alkyl, C1-6alkanoyl, carbamoyl, N—(C1-6alkyl)carbamoyl, N,N—(C1-6alkyl)carbamoyl, sulphamoyl, N—(C1-6alkyl)sulphamoyl, N,N—(C1-6alkyl)2sulphamoyl, C1-6alkoxycarbonyl, C1-6alkylsulphonyl, C1-6alkenylsulphonyl or heterocyclyl-R7;
- wherein R1 may be optionally substituted on carbon by one or more R8;
- and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R9;
- R7 is selected from —C(O)—, —C(O)N—(R15)—, —S(O)2— or —SO2N—(R16)—;
- wherein R15 and R16 are hydrogen;
- R8 is selected from halo, nitro, hydroxy, amino, C1-6alkyl, C1-6alkoxy, N—(C1-6alkyl)amino, N,N—(C1-6alkyl)2amino, carbocyclyl-R17— or heterocyclyl-R18—;
- wherein R8 may be optionally substituted on carbon by one or more R19;
- and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R20;
- R9 and R20 are independently selected from C1-6alkyl, C1-6alkanoyl, C1-6alkoxycarbonyl and benzyloxycarbonyl;
- wherein R9 and R20 independently of each other, may be optionally substituted on carbon by one or more R21;
- R17 and R18 are independently selected from a direct bond or —N—(R22)—;
- wherein R22 is selected from hydrogen or C1-6alkyl;
- and
- R19 and R21 are independently selected from halo, cyano, hydroxy, carbamoyl, methyl, propyl, cyclopropyl and methoxy.
11 more elements
4:
- A compound of formula (I), or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof, as claimed in claim 1 wherein q is 0.
5:
- A compound of formula (I), or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof, as claimed in claim 1 wherein R3 is halo.
6:
- A compound of formula (I), or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof, as claimed in claim 1 wherein n is 0 or 1.
7:
- A compound of formula (I), or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof, as claimed in claim 1 wherein R4 is selected from isopropyl or cyclopentyl.
8:
- A compound of formula (I), or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof, as claimed in claim 1 wherein R5 is methyl.
9:
- A compound of formula (I):
- wherein:
- Ring A is azepan-3-yl, (1α, 5α, 6α)-3-azabicyclo[3.1.0]hexan-3-yl, (R)-piperidin-3-yl, (S)-piperidin-3-yl, piperidin-4-yl, pyrrolidin-3-yl or endo-8-azabicyclo[3.2.1]octan-3-yl;
- R1 is a substituent on nitrogen and is selected from hydrogen, methyl, propyl, isopropyl, ethenylsulphonyl, mesyl, benzyloxycarbonyl, t-butoxycarbonyl, acetyl, phenethyl, ethoxycarbonyl, 2-methoxyethyl, sulphamoyl, N,N-dimethylsulphamoyl, N,N-dimethylcarbamoyl, benzyl, carbamoyl, N-methylcarbamoyl, 2-(dimethylamino)ethylsulphonyl, 2-(N-methyl-N-isopropyl)ethylsulphonyl, 2-(1-methylpiperazin-4-yl)ethylsulphonyl, 2-pyrrolidin-1-ylethylsulphonyl, 2-(3-fluoropyrrolidin-1-ylethylsulphonyl, 2-(thiomorpholin-4-yl)ethylsulphonyl, 2-(4-methylpiperidin-1-yl)ethylsulphonyl, 2-(homopiperidin-1-ylethylsulphonyl, 2-diethylaminoethylsulphonyl, 2-azetidin-1-ylethylsulphonyl, 2-morpholinoethylsulphonyl, 2-(4-fluoropiperidin-1-yl)ethylsulphonyl, 2-(4-cyanopiperidin-1-ylethylsulphonyl, 2-(4-propylpiperidin-1-ylethylsulphonyl, 2-(4-carbamoylpiperidin-1-ylethylsulphonyl, 2-(7-azabicyclo[2.2.1]hept-7-yl)ethylsulphonyl, 2-(2-azabicyclo[2.2.2]oct-2-yl)ethylsulfonyl, 2-(6-azabicyclo[2.2.2]oct-6-yl)ethylsulfonyl, 2-homomorpholinoethylsulphonyl, 2-(2-oxopiperazin-4-yl)ethylsulphonyl, 2-(1-acetylpiperazin-4-yl)ethylsulphonyl, 2-(2-methoxyethylamino)ethylsulphonyl, 2-(N-methyl-N-cyclopropyl)ethylsulphonyl, 2-(2-oxohomopiperazin-4-yl)ethylsulphonyl, 2-(1-acetylhomopiperazin-4-yl)ethylsulphonyl, 2-(N-methyl-N-cyclopropylmethyl)ethylsulphonyl 2-(homothiomorpholin-4-yl)ethylsulphonyl, 3-chloropropylsulphonyl, 3-dimethylaminopropylsulphonyl, 3-dimethylamino-2,2-dimethylpropylsulphonyl, 3-diethylaminopropylsulphonyl, 3-(2-methoxyethylamino)propylsulphonyl, 3-[N-methyl-N-(2-methoxyethyl)amino]propylsulphonyl, 3-hydroxypropylsulphonyl, 3-(1-hydroxyprop-2-ylamino)propylsulphonyl, 3-(1-methylpiperazin-4-yl)propylsulphonyl, 3-(1-isopropylpiperazin-4-yl)propylsulphonyl, 3-(6-azabicyclo[2.2.2]oct-6-yl)propylsulfonyl, 3-(7-azabicyclo[2.2.1]hept-7-yl)propylsulphonyl, 3-[1-(2-hydroxyethyl)piperazin-4-yl]propylsulphonyl, 3-pyrrolidin-1-ylpropylsulphonyl, 3-(1,4-dimethylpyrrolidin-1-yl)propylsulphonyl, 3-morpholinopropylsulphonyl, 3-(1-hydroxybut-2-ylamino)propylsulphonyl, 3-(1-methoxyprop-2-ylamino)propylsulphonyl, 3-(2-hydroxypropylamino)propylsulphonyl, 3-(1-hydroxy-3-methylbut-2-ylamino)propylsulphonyl, 3-(1-hydroxy-2-methylprop-2-ylamino)propylsulphonyl, 3-(piperidin-1-yl)propylsulphonyl, 3-(cyclopropylamino)propylsulphonyl, 3-(N-methyl-N-cyclopropylamino)propylsulphonyl, 3-(cyclopentylamino)propylsulphonyl, 3-(N-methyl-N-cyclopentylamino)propylsulphonyl, 3-(cyclobutylamino)propylsulphonyl, 3-(N-methyl-N-cyclobutylamino)propylsulphonyl, 3-(isopropylamino)propylsulphonyl, 3-(N-methyl-N-isopropylamino)propylsulphonyl, 3-(N-methyl-N-ethylamino)propylsulphonyl, 3-[N-methyl-N-(2-cyanoethyl)amino]propylsulphonyl, 3-[N-methyl-N-(2-cyanoethyl)amino]propylsulphonyl, 3-azetidin-1-ylpropylsulphonyl, 3-(cyclopropylmethylamino)propylsulphonyl, 3-(N-methyl-N-cyclopropylmethylamino)propylsulphonyl, 3-nitro-3-methylbutylsulphonyl, 3-amino-3-methylbutylsulphonyl, 3-dimethyl-3-methylbutylsulphonyl, 2-(piperidin-3-yl)acetyl, 2-(1--butoxycarbonylpiperidin-3-yl)acetyl, 2-(piperidin-4-yl)acetyl, 2-(1-t-butoxycarbonylpiperidin-4-yl)acetyl, 2-dimethylaminoacetyl, 3-(1-t-butoxycarbonylpiperazin-4-yl)propanoyl, 3-(1-t-butoxycarbonylpiperidin-4-yl)propanoyl, 3-(piperidin-4-yl)propanoyl. 3-(piperazin-4-yl)propanoyl, 3-dimethylaminopropanoyl, 4-morpholinobutanoyl, 4-dimethylaminobutanoyl, 1-t-butoxycarbonyl-4-methylpiperidin-4-ylcarbonyl, 4-methylpiperidin-4-ylcarbonyl, 1-t-butoxycarbonyl-4-methylpiperidin-4-ylcarbonyl, 4-methylhomopiperazin-1-ylcarbonyl, 1-methylpiperidin-3-ylcarbonyl, 1-methylpyrrolidin-2-ylcarbonyl, 3-dimethylaminopyrrolidin-1-ylcarbonyl, 4−/−butoxycarbonylmorpholin-2-ylcarbonyl, morpholin-2-ylcarbonyl, 1-methylpiperidin-4-ylcarbamoyl, N-(1-ethylpyrrolidin-2-ylmethyl)carbamoyl, N-(2-pyrrolidin-1-ylethyl)carbamoyl, N-(2-dimethylaminoethyl)carbamoyl, N-(1-methylpiperidin-4-yl)sulphamoyl, N-(1-isopropylpiperidin-4-yl)sulphamoyl, 2-(dimethylamino)ethylsulphamoyl, 2-(diethylamino)ethylsulphamoyl, 2-(morpholino)ethylsulphamoyl, 2-(1-methylpiperazin-4-yl)ethylsulphamoyl, 2-(1-methylpyrrolidin-2-yl)ethylsulphamoyl, 3-(pyrrolidin-1-yl)propylsulphamoyl, 3-(3-fluoropyrrolidin-1-yl)propylsulphamoyl, 3-dimethylamino-2,2-dimethylpropylsulphamoyl, 3-(piperidin-1-yl)propylsulphamoyl, N-methyl-N-(3-dimethylaminopropyl)sulphamoyl, 3-dimethylaminopyrrolidin-1-ylsulphonyl, 1-methylpiperazin-4-ylsulphonyl, 1-methylpiperidin-4-ylsulphonyl, 1-isopropylpiperidin-4-ylsulphonyl and 1-methylhomopiperazin-4-ylsulphonyl;
- q is 0;
- R3 is fluoro or chloro;
- n is 0 or 1;
- R4 is selected from isopropyl or cyclopentyl;
- R5 is methyl;
- or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof.
7 more elements
10:
- A compound of formula (I):
- selected from:
- 5-fluoro-4-(2-methyl-3-propan-2-yl-imidazol-4-yl)-N-(1-methylsulphonyl-4-piperidinyl)pyrimidin-2-amine;
- 5-fluoro-4-(2-methyl-3-propan-2-yl-imidazol-4-yl)-N-[1-(2-pyrrolidin-1-ylethylsulphonyl)-4-piperidinyl]pyrimidin-2-amine;
- N-[1-(3-dimethylamino-3-methyl-butyl)sulphonyl-4-piperidinyl]-5-fluoro-4-(2-methyl-3-propan-2-yl-imidazol-4-yl)pyrimidin-2-amine;
- N-[1-(3-chloropropylsulphonyl)-4-piperidinyl]-5-fluoro-4-(2-methyl-3-propan-2-yl-imidazol-4-yl)pyrimidin-2-amine;
- 5-fluoro-4-(2-methyl-3-propan-2-yl-imidazol-4-yl)-N-[1-(3-pyrrolidin-1-ylpropylsulphonyl)-4-piperidinyl]pyrimidin-2-amine;
- 5-fluoro-4-(2-methyl-3-propan-2-yl-imidazol-4-yl)-N-[1-[3-(1-piperidinyl)propylsulphonyl]-4-piperidinyl]pyrimidin-2-amine;
- N-[1-[2-(6-azabicyclo[2.2.2]oct-6-yl)ethylsulfonyl]-4-piperidinyl]-5-fluoro-4-(2-methyl-3-propan-2-yl-imidazol-4-yl)pyrimidin-2-amine;
- N-[1-[3-(6-azabicyclo[2.2.2]oct-6-yl)propylsulfonyl]-4-piperidinyl]-5-fluoro-4-(2-methyl-3-propan-2-yl-imidazol-4-yl)pyrimidin-2-amine;
- N-[1-[3-(7-azabicyclo[2.2.1]hept-7-yl)propylsulphonyl]-4-piperidinyl]-5-fluoro-4-(2-methyl-3-propan-2-yl-imidazol-4-yl)pyrimidin-2-amine;
- and
- 5-fluoro-4-(2-methyl-3-propan-2-yl-imidazol-4-yl)-N-[1-[(1-propan-2-yl-4-piperidinyl)sulfonyl]-4-piperidinyl]pyrimidin-2-amine;
- or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof.
11 more elements
11:
- A process for preparing a compound of formula (I) or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof, as claimed in claim 1, which process, wherein variable groups are, unless otherwise specified, as defined in claim 1, comprises:
- Process a) reacting a pyrimidine of formula (II):
- wherein L is a displaceable group;
- with an amine of formula (III):
- or
- Process b) reacting a compound of formula (IV):
- with a compound of formula (V):
- wherein T is O or S;
- Rx may be the same or different and is selected from C1-6alkyl;
- or
- Process c) reacting a pyrimidine of formula (VI):
- with a compound of formula (MI):
- where Y is a displaceable group;
- and thereafter optionally:
- i) converting a compound of the formula (I) into another compound of the formula (I);
- ii) removing any protecting groups;
- iii) forming a pharmaceutically acceptable salt or in vivo hydrolysable ester.
14 more elements
12:
- A pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as claimed in any one of claims 1, 9, 10 and a pharmaceutically-acceptable diluent or carrier.
13:
- A compound of the formula (I), or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as claimed in any one of claims 1, 9, 10, for use as a medicament.
14-18. (canceled)
19:
- A method of producing an anti-cell-proliferation effect, in a warm-blooded animal in need of such treatment, which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as claimed in any one of claims 1, 9, 10.
20:
- A method of producing a CDK2 inhibitory effect, in a warm-blooded animal in need of such treatment, which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as claimed in any one of claims 1, 9, 10.
21:
- A method of treating cancer, in a warm-blooded animal in need of such treatment, which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as claimed in any one of claims 1, 9, 10.
22:
- A method of treating leukaemia or lymphoid malignancies or cancer of the breast, lung, colon, rectum, stomach, liver, kidney, prostate, bladder, pancreas, vulva, skin or ovary, in a warm-blooded animal in need of such treatment, which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as claimed in any one of claims 1, 9, 10.
23:
- A method of treating cancer, fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis. Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation, in a warm-blooded animal in need of such treatment, which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as claimed in any one of claims 1, 9, 10.